971 related articles for article (PubMed ID: 15700039)
21. Prognostic significance of a positive nonsentinel lymph node in cutaneous melanoma.
Ghaferi AA; Wong SL; Johnson TM; Lowe L; Chang AE; Cimmino VM; Bradford CR; Rees RS; Sabel MS
Ann Surg Oncol; 2009 Nov; 16(11):2978-84. PubMed ID: 19711133
[TBL] [Abstract][Full Text] [Related]
22. High positive sentinel node identification rate by EORTC melanoma group protocol. Prognostic indicators of metastatic patterns after sentinel node biopsy in melanoma.
van Akkooi AC; de Wilt JH; Verhoef C; Graveland WJ; van Geel AN; Kliffen M; Eggermont AM
Eur J Cancer; 2006 Feb; 42(3):372-80. PubMed ID: 16403622
[TBL] [Abstract][Full Text] [Related]
23. Factors associated with false-negative sentinel lymph node biopsy in melanoma patients.
Scoggins CR; Martin RC; Ross MI; Edwards MJ; Reintgen DS; Urist MM; Gershenwald JE; Sussman JJ; Dirk Noyes R; Goydos JS; Beitsch PD; Ariyan S; Stromberg AJ; Hagendoorn LJ; McMasters KM
Ann Surg Oncol; 2010 Mar; 17(3):709-17. PubMed ID: 19967459
[TBL] [Abstract][Full Text] [Related]
24. Lymphatic invasion identified by monoclonal antibody D2-40, younger age, and ulceration: predictors of sentinel lymph node involvement in primary cutaneous melanoma.
Niakosari F; Kahn HJ; McCready D; Ghazarian D; Rotstein LE; Marks A; Kiss A; From L
Arch Dermatol; 2008 Apr; 144(4):462-7. PubMed ID: 18427039
[TBL] [Abstract][Full Text] [Related]
25. Sentinel lymph node biopsy in cutaneous melanoma: a case-control study.
Koskivuo I; Talve L; Vihinen P; Mäki M; Vahlberg T; Suominen E
Ann Surg Oncol; 2007 Dec; 14(12):3566-74. PubMed ID: 17924169
[TBL] [Abstract][Full Text] [Related]
26. Sentinel node biopsy in melanoma delays recurrence but does not change melanoma-related survival: a retrospective analysis of 673 patients.
Gutzmer R; Al Ghazal M; Geerlings H; Kapp A
Br J Dermatol; 2005 Dec; 153(6):1137-41. PubMed ID: 16307648
[TBL] [Abstract][Full Text] [Related]
27. Regional recurrence after negative sentinel lymph node biopsy for melanoma.
Carlson GW; Page AJ; Cohen C; Parker D; Yaar R; Li A; Hestley A; Delman KA; Murray DR
Ann Surg; 2008 Sep; 248(3):378-86. PubMed ID: 18791358
[TBL] [Abstract][Full Text] [Related]
28. Impact of false-negative sentinel lymph node biopsy on survival in patients with cutaneous melanoma.
Caracò C; Marone U; Celentano E; Botti G; Mozzillo N
Ann Surg Oncol; 2007 Sep; 14(9):2662-7. PubMed ID: 17597345
[TBL] [Abstract][Full Text] [Related]
29. Comparison of metallothionein-overexpression with sentinel lymph node biopsy as prognostic factors in melanoma.
Weinlich G; Topar G; Eisendle K; Fritsch PO; Zelger B
J Eur Acad Dermatol Venereol; 2007 May; 21(5):669-77. PubMed ID: 17447982
[TBL] [Abstract][Full Text] [Related]
30. [Sentinel lymph node dissection in patients with malignant melanoma. Diagnostic and therapeutic standards].
Arens A; Osinga J; Schwipper V; Schober O; Tilkorn H; Liebau J
Chirurg; 2003 Jul; 74(7):665-70. PubMed ID: 12883795
[TBL] [Abstract][Full Text] [Related]
31. Sentinel lymph node biopsy for cutaneous melanoma: the Stanford experience, 1997-2004.
Berk DR; Johnson DL; Uzieblo A; Kiernan M; Swetter SM
Arch Dermatol; 2005 Aug; 141(8):1016-22. PubMed ID: 16103331
[TBL] [Abstract][Full Text] [Related]
32. Is there a benefit to sentinel lymph node biopsy in patients with T4 melanoma?
Gajdos C; Griffith KA; Wong SL; Johnson TM; Chang AE; Cimmino VM; Lowe L; Bradford CR; Rees RS; Sabel MS
Cancer; 2009 Dec; 115(24):5752-60. PubMed ID: 19827151
[TBL] [Abstract][Full Text] [Related]
33. [Important prognostic significance of a sentinel-node biopsy in patients with malignant melanoma].
Keijzer R; Bril H; van der Loo EM; de Graaf PW
Ned Tijdschr Geneeskd; 2004 May; 148(18):884-8. PubMed ID: 15152391
[TBL] [Abstract][Full Text] [Related]
34. Sentinel lymph node biopsy in elderly irish patients with malignant melanoma.
Moran DE; Smith MJ; O'Sullivan MJ; Bannon H; Crotty TB; Collins CD; Skehan SJ; O'Higgins N; McDermott EW; Evoy D; Hill AD
Ir Med J; 2007 Apr; 100(4):422-4. PubMed ID: 17566474
[TBL] [Abstract][Full Text] [Related]
35. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma.
Azimi F; Scolyer RA; Rumcheva P; Moncrieff M; Murali R; McCarthy SW; Saw RP; Thompson JF
J Clin Oncol; 2012 Jul; 30(21):2678-83. PubMed ID: 22711850
[TBL] [Abstract][Full Text] [Related]
36. Size of sentinel node metastases predicts other nodal disease and survival in malignant melanoma.
Pearlman NW; McCarter MD; Frank M; Hurtubis C; Merkow RP; Franklin WA; Gonzalez R; Lewis K; Roaten JB; Robinson WA
Am J Surg; 2006 Dec; 192(6):878-81. PubMed ID: 17161112
[TBL] [Abstract][Full Text] [Related]
37. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma.
Taylor RC; Patel A; Panageas KS; Busam KJ; Brady MS
J Clin Oncol; 2007 Mar; 25(7):869-75. PubMed ID: 17327608
[TBL] [Abstract][Full Text] [Related]
38. Role of sentinel lymph node biopsy in patients with thick (>4 mm) primary melanoma.
Jacobs IA; Chang CK; Salti GI
Am Surg; 2004 Jan; 70(1):59-62. PubMed ID: 14964550
[TBL] [Abstract][Full Text] [Related]
39. Prognostic implications of anatomic location of primary cutaneous melanoma of 1 mm or thicker.
Callender GG; Egger ME; Burton AL; Scoggins CR; Ross MI; Stromberg AJ; Hagendoorn L; Martin RC; McMasters KM
Am J Surg; 2011 Dec; 202(6):659-64; discussion 664-5. PubMed ID: 22137134
[TBL] [Abstract][Full Text] [Related]
40. Sentinel lymph node tumor load: an independent predictor of additional lymph node involvement and survival in melanoma.
Vuylsteke RJ; Borgstein PJ; van Leeuwen PA; Gietema HA; Molenkamp BG; Statius Muller MG; van Diest PJ; van der Sijp JR; Meijer S
Ann Surg Oncol; 2005 Jun; 12(6):440-8. PubMed ID: 15864481
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
